CRIS Current Research Information System

TACCHETTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.716
AS - Asia 4.938
EU - Europa 3.932
AF - Africa 386
SA - Sud America 278
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.255
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.661
CN - Cina 1.474
SG - Singapore 1.365
VN - Vietnam 1.172
IT - Italia 851
GB - Regno Unito 837
SE - Svezia 520
DE - Germania 499
HK - Hong Kong 328
IN - India 246
NL - Olanda 204
BR - Brasile 197
RU - Federazione Russa 195
FR - Francia 169
KR - Corea 163
IE - Irlanda 161
CI - Costa d'Avorio 147
UA - Ucraina 129
FI - Finlandia 79
TG - Togo 79
ZA - Sudafrica 76
SC - Seychelles 62
EE - Estonia 59
JP - Giappone 52
BG - Bulgaria 46
CH - Svizzera 43
AR - Argentina 38
BE - Belgio 35
CA - Canada 35
AT - Austria 30
JO - Giordania 30
PL - Polonia 21
ID - Indonesia 18
IR - Iran 18
MX - Messico 17
ES - Italia 15
NG - Nigeria 14
CO - Colombia 12
EC - Ecuador 12
LB - Libano 11
BD - Bangladesh 10
CZ - Repubblica Ceca 10
TR - Turchia 10
CL - Cile 9
IL - Israele 8
PH - Filippine 8
GR - Grecia 6
LT - Lituania 5
UZ - Uzbekistan 5
PY - Paraguay 4
RO - Romania 4
IQ - Iraq 3
PE - Perù 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CY - Cipro 2
GH - Ghana 2
HR - Croazia 2
MA - Marocco 2
PT - Portogallo 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
MY - Malesia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
VE - Venezuela 1
ZM - Zambia 1
Totale 15.255
Salva come PNG Salva come JPEG
Città #
Singapore 892
Ashburn 749
Southend 715
Fairfield 586
Chandler 570
Hefei 362
Hong Kong 327
Woodbridge 276
Seattle 257
Ho Chi Minh City 247
Bologna 245
Wilmington 241
Ann Arbor 223
Cambridge 215
Beijing 213
Houston 212
Hanoi 195
Dong Ket 178
Dallas 173
Princeton 170
Seoul 162
Santa Clara 160
Dublin 157
Abidjan 147
Boardman 123
Los Angeles 86
New York 85
Lomé 79
Jacksonville 69
Nanjing 69
Bremen 66
Westminster 66
Padova 62
Helsinki 57
Berlin 52
Milan 52
Tokyo 49
Jinan 48
Sofia 45
Hyderabad 44
Turin 44
Munich 42
Buffalo 41
Frankfurt am Main 39
San Diego 38
Shenyang 38
Haiphong 37
Redondo Beach 35
Bengaluru 34
Bern 34
Saint Petersburg 34
Brussels 33
Redwood City 33
Changsha 31
Amman 30
Nanchang 27
Redmond 26
São Paulo 25
Zhengzhou 25
Tianjin 24
Fabriano 22
Hebei 22
Amsterdam 21
Florence 21
Falkenstein 20
Jiaxing 19
Nuremberg 19
Rome 19
Vienna 19
Guangzhou 18
Shanghai 18
Ha Long 17
London 17
Hangzhou 16
Washington 16
Mülheim 15
Norwalk 15
Chicago 14
Dongguan 14
Abeokuta 13
Da Nang 13
Falls Church 13
Medford 13
Quận Bình Thạnh 13
Toronto 13
Biên Hòa 12
Brooklyn 12
Dearborn 12
Jakarta 12
Kunming 12
Lappeenranta 12
Monmouth Junction 12
Ninh Bình 12
Paris 12
Shenzhen 12
Thái Nguyên 12
Tongling 12
Council Bluffs 11
Des Moines 11
Phoenix 11
Totale 9.991
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 663
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 280
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 267
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 229
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 229
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 229
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 206
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 205
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 198
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 193
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 193
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 184
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 181
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 181
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 179
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 178
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 178
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 177
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 176
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 175
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 175
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 173
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 173
Thalidomide maintenance in multiple myeloma: certainties and controversies. 171
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 169
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 168
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 168
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 167
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 166
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 162
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 162
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 161
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 159
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 158
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 158
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 157
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 157
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 155
Dermoscopy of cutaneous involvement by multiple myeloma 155
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 150
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 148
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 148
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 147
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 147
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 146
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 146
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 145
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 144
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 140
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 140
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 139
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 137
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 136
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 133
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 133
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 132
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 132
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 131
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 129
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 128
Role of consolidation therapy in transplant eligible multiple myeloma patients. 127
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 124
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 123
Imaging in multiple myeloma: How? When? 123
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 123
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 122
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 122
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 122
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 121
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. 119
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 118
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 118
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 117
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 115
Extramedullary metastatic plasmacytoma in a multiple myeloma patient 115
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 114
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 110
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 110
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 107
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 107
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. 104
Multiple myeloma: disease response assessment 103
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 100
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 100
null 98
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 96
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 95
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 93
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 81
Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM 80
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 79
null 77
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 74
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 73
Proteasome inhibitors: Bortezomib in multiple myeloma 73
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 73
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 72
Totale 14.905
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.574
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.574
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021870 0 0 0 0 0 52 44 72 125 62 82 433
2021/20221.727 180 75 98 132 157 79 33 117 65 173 311 307
2022/20232.299 211 354 102 356 144 204 77 121 358 78 174 120
2023/2024761 45 114 49 59 69 187 35 94 9 31 42 27
2024/20252.602 136 295 220 212 279 125 205 95 60 293 183 499
2025/20263.971 716 1.181 614 562 687 211 0 0 0 0 0 0
Totale 15.567